Phase I Clinical Study of HWH340 Tablet in Patients With Advanced Solid Tumors

NCT03415659 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

85

Enrollment

OTHER

Sponsor class

Conditions

Advanced Solid Tumors
HRD
BRCA Mutation

Interventions

DRUG: HWH340 tablet

Sponsor

Hubei Biological Medicine Industrial Technology Institute Co., Ltd.